🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

UPDATE 1-Russia's Gamaleya applies for emergency vaccine use in Philippines

Published 01/09/2021, 12:52 PM
Updated 01/09/2021, 01:00 PM
AZN
-
SVA
-

* Gamaleya becomes third to apply for emergency use in
Philippines
* China's Clover approved for late-stage clinical trials
* Philippines has second-highest COVID-19 cases, deaths in
SEAsia

(Adds details on Clover, regulator quote, background)
MANILA, Jan 9 (Reuters) - Russia's Gamaleya Research
Institute has applied to the Philippine health regulator for
emergency use authorisation of its COVID-19 vaccine but needs to
file further documentation, the regulator said late Friday.
Gamaleya's emergency use application is the third the
Philippine Food and Drug Administration (FDA) has received after
Pfizer PFE.N and AstraZeneca AZN.L both made similar
applications. "The submission was pre-assessed and the applicant was
instructed to comply with the lacking documents," FDA Director
General Rolando Enrique Domingo said in a statement.
The agency also approved on Friday the application of
China's Clover Biopharmaceuticals to conduct late-stage clinical
trials in the Philippines, he added.
Clover is the second Chinese developer to apply for Phase
III clinical trials in the Philippines following Sinovac Biotech
SVA.O . In December, the FDA allowed a clinical trial for the
COVID-19 vaccine of Johnson & Johnson's JNJ.N unit Janssen.
Philippine President Rodrigo Duterte has vowed free vaccines
for the entire 108 million population to help the battered
economy recover from the pandemic.
The Philippines has the second-highest number of COVID-19
cases and deaths in Southeast Asia, after Indonesia.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.